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Aims: To investigate the occurrence of CF-related bone disease (CFRBD) in a
sample of our patients, know their features, and identify potential risk factors.
Methods: 42 patients had bone mass density measurements (BDM). Clinical
features, genotype, and biochemical markers of bone health were assessed.
Results: Mean age was 25.3±6.6 years, 54.8% were male and 85.7% had PI.
Mean FEV1 was 75.6%. 45% were F508del homozygotes, and 35.7% F508del
heterozygotes. Mean BMI was 21.3±2.5, and in 6 was <19 kg/m2. 12 patients
(28.2%) had liver disease, and 6 (14.3%) had CF-related diabetes. Most had
abnormal values of one or more biochemical markers. Low serum levels of
25-OHvitamin D were found in 19 (44.4%), osteocalcin in 11 (25.3%) and bone
alkaline phosphatase in 3 (6.45%). PTH serum levels were raised in 9 (21.6%) and
those of C terminal telopeptide in 27 (63.6%). Signiﬁcant correlations were found
between values of most of the markers. BMD measurements of femoral neck and
lumbar spine were performed and results expressed as T and Z scores (Tsc and Zsc),
showed evidence of osteoporosis in 4 (9.5%) and osteopenia in 21 (50%). There
was a signiﬁcant association between CF genotype and femoral Tsc (p = 0.003),
and between pancreatic function and both femoral (p = 0.024) and lumbar spine
(p = 0.045) Tsc.
Conclusions:
1. Low BMD results were less common than in other studies. Still the high
frequency of abnormalities in the biochemical markers indicate a trend towards
bone mass loss in most patients.
2. Correct nutrition and adequate vitamin supplementation, as well as regular BMD
measurements and biochemical markers determinations are essential for the early
detection of CFRBD.
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Introduction: Cystic ﬁbrosis (CF) is a chronic, genetic disease, which affects worse
physical development and nutritional status as well as bone metabolism disturbances
in children and adults. Bone mass loss in children could be caused by various
mechanisms, most probably because of imbalance between bone formation and
degradation processes. CF-related low bone mineral density (BMD) leads to bone
fragility, susceptibility to fracture and disability.
Aim of the study was to assess the bone mass density in children with CF.
Material and Methods: The study group included 20 patients with CF −
65% males, 35% females. Mean age was 11.5 (5.9–19.1), 12 patients (60%) were
under 3rd percentile of body weight. Examination of bone mass density (L2-L4
BMD) by DEXA method using DPX-L (Lunar) was carried out. The results were
expressed as Z-score. Vitamin D and calcium levels were also measured.
Results: DEXA results showed: 10 patients (50%) with normal DEXA scan
[Z-score: (>−1)], 6 (30%) with CF-related low BMD [Z-score (<−2)] and 4 (20%)
children with signiﬁcantly reduced BMD [Z-score: (−1.5)–(−2.0)]. Low BMD was
connected with body weight under 3rd percentile in our patients.
Conclusion: There is a risk of osteopenia or osteoporosis in our group of children
with CF, however to characterize these abnormalities, more thorough research on a
larger group of patients is needed.
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Background: Reduced Bone Mass Density (BMD) is frequent in adults with
Cystic Fibrosis (CF). In children, study results are discordant. Dual energy X-ray
absorptiometry (DXA) is the reference method for determining bone mineral
density (BMD). Quantitative ultrasound sonography (QUS) for bone measurement
is a relatively new, inexpensive and radiation-free method that could serve as an
alternative to DXA.
Aim: To assess bone status and to compare QUS with DXA, in identifying
osteopenia and osteoporosis among CF patients.
Methods: Thirty patients (10 male, mean age: 15.42±4.68) with CF, participated
in the study. All patients were evaluated with QUS at radius and tibia and had DXA
scan at lumbar spine vertebrae (L2-L4).
Results: The mean Shwachman-Kulczycki score of CF patients were indicative of
well-controlled disease. The anthropometric measurements, mean serum calcium,
phosphorus, ALP and parathyroid hormone levels were within normal range. BMD
Z-scores were 0.05 ±1.3 (mean±SD) at the Lumbar spine. Based on a lumbar
spine z-score by DEXA, 16.7% of the patients had osteopenia, and none had
osteoporosis. QUS measurements at radius were correlated to BMD measured
at lumbar spine (r = 0.47, p = 0.024), while QUS measurements at tibia were not
(r = 0.023, p = 0.919). Finally, no agreement was recorded between the two methods
in identifying CF patients at risk for osteoporosis.
Conclusion: No patients of the study population had osteoporosis, while 16.7% of
the patients had osteopenia. QUS is not as sensitive as DXA in assessing osteopenia
and osteoporosis among children and adolescents with well-controlled CF.
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Background: Markers of bone remodeling have been developed that provide
biochemical indices that reﬂect changes in the rates of bone formation, resorption
and mineralization. These processes are important determinants of bone metabolism
and indicators that correspond to these processes can provide clinically relevant
information.
Purpose: To determine the proﬁle of main bone turnover markers in children with
cystic ﬁbrosis.
Materials: 70 children age of 10−17 years with cystic ﬁbrosis had been examined.
Methods: Level of osteocalcin and C-terminal cross-linking telopeptides were
estimated in blood samples with the application of immunoenzyme analysis method-
ology and standardized sets.
Results: The highest level of bone markers were obtained in patients of both
sexes age of 10−13 years that reﬂects the maximum of height velocity and bone
mineralisation in this period. Bone turnover markers increased signiﬁcantly until
maximum values were reached at stage G4 in boys and stage B3 in girls and
statistically signiﬁcant decreased after 14 years age (p< 0.05). Correlation was
determined between the level of osteocalcin and the age of patients: r = 0.50
(p< 0.05). Furthermore, relationship had been established between the level of these
two markers: r = 0.71 (p< 0.05), that reﬂects equal intensity of bone formation and
resorption.
Conclusion: Osteocalcin and C-terminal cross-linking telopeptides may be useful
for monitoring of growth in children with cystic ﬁbrosis.
